MyMD Pharmaceuticals, Inc.

Symbol: MYMD




Market price today

  • -1.3690

    P/E Ratio

  • -0.0365

    PEG Ratio

  • 5.18M

    MRK Cap

  • 0.00%

    DIV Yield

MyMD Pharmaceuticals, Inc. (MYMD) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Christopher C. Chapman Jr., M.D.
Full-time employees:6
Address:855 North Wolfe Street

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

General Outlook

In simple terms, MyMD Pharmaceuticals, Inc. has 2.158 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -0.164% return, is a testament to MyMD Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. MyMD Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.218%. Furthermore, the proficiency of MyMD Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -1.330% return on capital employed.

Stock Prices

MyMD Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.45, while its low point bottomed out at $2.24. This variance in figures offers investors a lucid insight into the roller-coaster ride that is MyMD Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing MYMD liquidity ratios reveals its financial health of the firm. The current ratio of 116.60% gauges short-term asset coverage for liabilities. The quick ratio (98.70%) assesses immediate liquidity, while the cash ratio (53.75%) indicates cash reserves.

Current Ratio116.60%
Quick Ratio98.70%
Cash Ratio53.75%

Profitability Ratios

The effective tax rate stands at 2.38%, revealing its tax efficiency. The net income per EBT, 73.03%, and the EBT per EBIT, 23.36%, provide insights into its earnings hierarchy.

Effective Tax Rate2.38%
Net Income per EBT73.03%
EBT per EBIT23.36%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.17, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

Days of Sales Outstanding99

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -7.79, and free cash flow per share, -7.79, depict cash generation on a per-share basis. The cash per share value, 2.95, showcases liquidity position. A payout ratio of -0.61 highlights the portion of earnings distributed as dividends.

Operating Cash Flow per Share-7.79
Free Cash Flow per Share-7.79
Cash per Share2.95
Payout Ratio-0.61
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-265.62
Short Term Coverage Ratio-265.62
Dividend Paid and Capex Coverage Ratio-7.27
Dividend Payout Ratio0.12

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.27%, highlights its total liabilities relative to assets. An interest coverage of 15.88 indicates its ability to manage interest expenses.

Debt Ratio0.27%
Total Debt to Capitalization0.38%
Interest Coverage15.88
Cash Flow to Debt Ratio-265.62
Company Equity Multiplier1.40

Per Share Data

Net income per share, -2.59, reflects the portion of profit attributed to each share. The book value per share, 8.28, represents the net asset value distributed per share, while the tangible book value per share, 1.47, excludes intangible assets.

Net Income Per Share-2.59
Book Value Per Share8.28
Tangible Book Value Per Share1.47
Shareholders Equity Per Share8.28
Interest Debt Per Share0.03

Growth Ratios

EBIT growth, -12.04%, and operating income growth, -12.04%, offer insights into operational profitability progression. The net income growth, 45.62%, showcases bottom-line expansion, and the EPS growth, 54.37%, measures the growth in earnings per share.

EBIT Growth-12.04%
Operating Income Growth-12.04%
Net Income Growth45.62%
EPS Growth54.37%
EPS Diluted Growth54.37%
Weighted Average Shares Growth19.18%
Weighted Average Shares Diluted Growth19.18%
Operating Cash Flow Growth100.00%
Free Cash Flow Growth100.00%
10-Year Revenue Growth per Share-100.00%
5-Year Revenue Growth per Share-100.00%
10-Year Operating CF Growth per Share100.00%
5-Year Operating CF Growth per Share100.00%
3-Year Operating CF Growth per Share100.00%
10-Year Net Income Growth per Share97.10%
5-Year Net Income Growth per Share77.54%
3-Year Net Income Growth per Share94.14%
10-Year Shareholders Equity Growth per Share-100.01%
5-Year Shareholders Equity Growth per Share-100.46%
3-Year Shareholders Equity Growth per Share99.87%
Asset Growth-174.01%
Book Value per Share Growth-100.51%
Debt Growth-100.00%
R&D Expense Growth-13.23%
SGA Expenses Growth-100.00%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 9,337,411.68, captures the company's total value, considering both debt and equity. Income quality, 3.25, assesses the reliability of reported earnings.

Enterprise Value9,337,411.68
Income Quality3.25
Intangibles to Total Assets58.77%
Graham Number21.98
Return on Tangible Assets-54.32%
Graham Net Net-0.11
Working Capital828,253
Tangible Asset Value2,275,104
Net Current Asset Value727,715
Average Payables3,036,386.5

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.31, and the price to book ratio, 0.31, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -0.40, and price to operating cash flows, -0.31, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.31
Price to Book Ratio0.31
Price Cash Flow Ratio-0.31
Price Earnings to Growth Ratio-0.04
Enterprise Value Multiple-0.29
Price Fair Value0.31
Price to Operating Cash Flow Ratio-0.31
Price to Free Cash Flows Ratio-0.40
Price to Tangible Book Ratio0.94
Enterprise Value Over EBITDA-0.55
EV to Operating Cash Flow-0.72
Earnings Yield-33.42%
Free Cash Flow Yield-108.45%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of MyMD Pharmaceuticals, Inc. (MYMD) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -1.369 in 2024.

What is the ticker symbol of MyMD Pharmaceuticals, Inc. stock?

The ticker symbol of MyMD Pharmaceuticals, Inc. stock is MYMD.

What is company IPO date?

IPO date of MyMD Pharmaceuticals, Inc. is 2014-01-23.

What is company current share price?

Current share price is 2.400 USD.

What is stock market cap today?

The market cap of stock today is 5178312.000.

What is PEG ratio in 2024?

The current -0.037 is -0.037 in 2024.

What is the number of employees in 2024?

In 2024 the company has 6.